Aberman Zami 4
4 · PLURISTEM THERAPEUTICS INC · Filed Feb 14, 2022
Insider Transaction Report
Form 4
Aberman Zami
DirectorCEO & Co. Chairman
Transactions
- Purchase
Common Stock
2022-02-10$1.80/sh+80,616$145,109→ 91,756 total(indirect: By Rose Hitech Ltd.)
Holdings
- 1,493,973
Common Stock
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on the Tel Aviv Stock Exchange in New Israeli Shekels (NIS), at per share purchase prices ranging from NIS 5.70 to NIS 5.90, inclusive, or ranging from $1.77 to $1.82 in U.S. Dollars, inclusive (based on an exchange rate of NIS 3.221 per U.S. dollar). The Reporting Person undertakes to provide to Pluristem Therapeutics Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).